SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris presented positive Phase 3 RAPIDe-3 data at EAACI 2026,…

Pharvaris N.V. · PRESS-RELEASE filed Jun 15, 2026 at 06:50 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 15, 2026 at 06:50 ET

Pharvaris presented positive Phase 3 RAPIDe-3 data at EAACI 2026, showing deucrictibant achieved a median time to onset of symptom relief of 1.28 hours vs >12 hours for placebo, and median time to complete resolution of 11.95 hours vs >48 hours. The majority of attacks (83.0%) were treated with a single capsule, and 93.2% required no rescue medication. Long-term prophylaxis data from CHAPTER-1 OLE showed ~92% reduction in attack rates and 100% of participants reporting well-controlled disease. The company is preparing NDA submission for on-demand treatment and expects topline data from the pivotal CHAPTER-3 prophylaxis study in Q3 2026.

  • RAPIDe-3 Phase 3: median time to onset of symptom relief 1.28 hours (deucrictibant) vs >12 hours (placebo)
  • Median time to complete resolution: 11.95 hours (deucrictibant) vs >48 hours (placebo)
  • 83.0% of attacks treated with a single capsule; 93.2% required no rescue medication
  • CHAPTER-1 OLE: ~92% reduction in HAE attack rates; ~50% of participants attack-free during entire extension

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access